乙型肝炎肝硬化合并骨质疏松患者临床干预的安全性研究  

Safety Study of Clinical Intervention in Patients with Hepatitis B Cirrhosis Complicated with Osteoporosis

作　　者：张怀琼 ZHANG Huaiqiong(Tianjin second people's hospital,Tianjin 300100)

机构地区：[1]天津市第二人民医院,天津300100

出　　处：《中国伤残医学》2024年第8期1-4,共4页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探究乙型肝炎肝硬化合并骨质疏松患者同时给予抗病毒治疗及抗骨质疏松治疗的安全性.方法:选取我院2020年1月—2022年12月收治的74例乙型肝炎肝硬化合并骨质疏松患者为研究对象,按照随机数字表法将其分为对照组与试验组,每组37例.对照组采用抗病毒药物治疗,试验组在对照组基础上采用抗骨质疏松药物治疗.比较2组患者的肝功能、病毒载量、肝硬度、关键位置骨密度及不良反应发生情况.结果:入院时,入院6、12个月后,2组肝功能、病毒载量、肝硬度情况比较,组间差异无统计学意义(P>0.05).入院6、12个月后,试验组腰椎L_(2~4),股骨颈骨密度均大于对照组,组间差异有统计学意义(P<0.05).2组不良反应发生率比较,差异无统计学意义(P>0.05).结论:同步给予乙型肝炎肝硬化联合骨质疏松患者抗病毒及抗骨质疏松药物治疗安全性较好,增用抗骨质疏松药物在改善患者骨质疏松病情的同时未对患者肝功能产生不利影响.Objective:To explore the safety of antiviral therapy and anti-osteoporosis therapy in patients with hepatitis B cirrhosis combined with osteoporosis.Methods:74 patients with hepatitis B cirrhosis complicated with osteoporosis admitted to our hospital from January 2020 to December 2022 were selected as the study objects,and were divided into a control group and an experimental group according to random number table method,with 37 cases in each group.The control group was treated with antiviral drugs,and the experimental group was treated with anti-osteoporosis drugs based on the control group.Liver function,viral load,liver hardness,bone mineral density at key sites and adverse reactions were compared between the two groups.Results:At admission,6 and 12 months after admission,there were no significant differences in liver function,viral load and liver hardness between the two groups(P>0.05).6 and 12 months after admission,BMD of lumbar L_(2~4) and femoral neck in experimental groups were greater than those in control group,and the differences between groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Simultaneous administration of antiviral and anti-osteoporosis drugs in patients with hepatitis B cirrhosis combined with osteoporosis is safe,and increased use of anti-osteoporosis drugs can improve the condition of osteoporosis without adverse effects on the liver function of patients.

关 键 词：乙型肝炎肝硬化 肝性骨病 联合用药治疗 临床治疗安全性 

分 类 号：R512.62[医药卫生—内科学] R580[医药卫生—临床医学]